Clinical Trial - Autologous Dendritic Cells Loaded with Idiotype (APC8020i) Combined With Thalidomide for the Treatment of Multiple Myeloma

Title:	Autologous Dendritic Cells Loaded with Idiotype (APC8020i) Combined With Thalidomide for the Treatment of Multiple Myeloma

Phase:	II

Purpose:	To determine the safety and effectiveness of administering APC8020i in combination with thalidomide to patients with multiple myeloma

Eligibility:	Currently on thalidomide for at least 8 weeks with no evidence of progression. Measurable disease in the blood Adequate kidney and liver functions No history of cardiac disease No active infection

Treatment:	Patients will continue to take thalidomide as previously prescribed. Patients will undergo leukapheresis to collect dendritic cells from their blood. These dendritic cells will be used to make APC8020i, a therapeutic cancer vaccine. Patients will then return to receive treatment with the APC8020i vaccine. These procedures will be repeated for a total of 3 leukaphereses and 3 treatments over the course of 5 weeks

Contact:	New York Dr Michael Schuster New York Presbyterian Hospital Weill Medical College of Cornell University 212-746-2459

Please note: the trials indicated do not include the full inclusion or exclusion criteria. For full protocols, please contact the Principal Investigator (PI) listed.